Breakthrough Studies
Stay updated on groundbreaking scientific research and medical discoveries. This section highlights significant studies shaping the future of healthcare and treatment.
Researchers discover why some colon cancers resist treatment
Researchers at The Tisch Cancer Institute at Mount Sinai have uncovered a major reason why some colorectal cancers (CRC) resist treatment.
Metastasis-Directed Therapy for Prostate Cancer a Clear Winner in Meta-Analysis
PFS more than doubled with standard of care plus MDT, but practice continues to evolve
A newly discovered biomarker can predict cancer aggressiveness
Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers.
Innovative molecular therapies target and disrupt uncontrollable growth of cancer cells
wo new studies represent a big step toward developing innovative molecular therapies capable of disrupting the uncontrollable growth of cancers at their roots.
AI could detect cancer in abdomen early, study finds
Artificial intelligence (AI) is becoming an essential tool in medical imaging, helping radiologists analyze scans faster and more accurately. However, AI models need a massive amount of labeled data to work well, which means radiologists still spend a lot of time marking images manually.
Researchers develop T cell growth method that enhances cancer-fighting ability in melanoma model
Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.
TROPION-Lung12 phase 3 trial initiated evaluating Datroway as part of adjuvant regimen for patients with early-stage NSCLC at high risk of relapse
he first patient has been dosed in the TROPION-Lung12 phase 3 trial evaluating the efficacy and safety of adjuvant Datroway (datopotamab deruxtecan) plus rilvegostomig or rilvegostomig monotherapy versus standard of care in patients with stage 1 adenocarcinoma non-small cell lung cancer (NSCLC) after complete surgical resection who are ctDNA-positive or have other high risk pathological features.
Moffitt Cancer Center Announces New Proton Therapy Treatment
Moffitt Cancer Center has introduced a new proton therapy treatment, offering advanced options for cancer patients.
World Cancer Day 2025: Progress in Awareness and Treatment – The Open News
World Cancer Day, an annual global event aimed at increasing awareness of cancer, advancing education, and spurring action to eradicate the illness, is celebrated on February 4th. As World Cancer Day 2025 approaches, it’s a chance to acknowledge the enormous progress that has been made in cancer awareness, early detection, and treatment while also acknowledging […]
CD5 CAR-T Cell Therapy Receives FDA Orphan Drug Designation for T-Cell Lymphoma
MB-105 is a first-in-class CD5-targeted chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory CD5-positive T-cell lymphoma.
Phase II Study Explores Chemo-Free Regimen for HER2-Altered … : Oncology Times
A recent Phase II study has explored the potential of a chemotherapy-free regimen for treating certain cancer patients, offering a promising alternative to traditional chemo-based therapies
Cancer vaccine being created by scientists could stop disease up to 20 years early
A new partnership between the University of Oxford and GSK aims to develop vaccines against cancer before develop
